Zacks: Analysts Anticipate Curis, Inc. (CRIS) Will Announce Earnings of -$0.22 Per Share

Share on StockTwits

Wall Street brokerages expect that Curis, Inc. (NASDAQ:CRIS) will announce earnings of ($0.22) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Curis’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.22). Curis posted earnings of ($0.25) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 12%. The business is expected to announce its next earnings report on Thursday, March 14th.

On average, analysts expect that Curis will report full year earnings of ($1.05) per share for the current financial year, with EPS estimates ranging from ($1.11) to ($1.01). For the next year, analysts forecast that the business will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.12) to ($0.72). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Curis.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.09. The business had revenue of $2.85 million for the quarter, compared to analyst estimates of $2.38 million. Curis had a negative net margin of 316.98% and a negative return on equity of 299.20%.

Several analysts recently issued reports on the stock. Cowen reiterated a “buy” rating on shares of Curis in a research report on Tuesday, September 25th. Zacks Investment Research lowered shares of Curis from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Finally, SunTrust Banks reduced their price target on shares of Curis to $8.00 and set a “buy” rating on the stock in a research report on Friday, August 3rd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $13.33.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC acquired a new stake in shares of Curis during the 2nd quarter worth approximately $540,000. Paloma Partners Management Co acquired a new stake in shares of Curis during the 2nd quarter worth approximately $223,000. JPMorgan Chase & Co. boosted its position in shares of Curis by 780.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 73,954 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 65,554 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Curis during the 2nd quarter worth approximately $124,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Shares of NASDAQ CRIS traded down $0.11 during trading hours on Friday, hitting $1.56. 220,084 shares of the stock were exchanged, compared to its average volume of 301,291. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 38.74. The firm has a market capitalization of $52.65 million, a price-to-earnings ratio of -0.87 and a beta of 1.16. Curis has a 1-year low of $1.36 and a 1-year high of $7.17.

About Curis

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Recommended Story: How are the companies in the S&P 500 selected?

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply